Littérature scientifique sur le sujet « Cisplatin »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Cisplatin ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Cisplatin"
ATAMAN, J. E., et D. BAXTER-GRILLO. « MORPHOLOGICAL EVALUATION OF CISPLATIN-INDUCED TESTICULAR DAMAGE IN WISTAR RATS ». Nigerian Journal of Life Sciences (ISSN : 2276-7029) 4, no 1 (17 mars 2022) : 16–25. http://dx.doi.org/10.52417/njls.v4i1.151.
Texte intégralMonroe, Jerry D., Denis Hodzic, Matthew H. Millay, Blaine G. Patty et Michael E. Smith. « Anti-Cancer and Ototoxicity Characteristics of the Curcuminoids, CLEFMA and EF24, in Combination with Cisplatin ». Molecules 24, no 21 (29 octobre 2019) : 3889. http://dx.doi.org/10.3390/molecules24213889.
Texte intégralHeiserman, James Patrick, Zenab Minhas, Elahe Nikpayam et Dong-Joo Cheon. « Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines ». International Journal of Molecular Sciences 24, no 16 (10 août 2023) : 12638. http://dx.doi.org/10.3390/ijms241612638.
Texte intégralCHEN, PING, QING-SHENG WU, YA-PING DING et ZI-CHUN ZHU. « PREPARATION OF CISPLATIN COMPOSITE MICRO/NANOFIBERS AND ANTITUMOR ACTIVITY IN VITRO AGAINST HUMAN TUMOR spc-a-1 CELLS ». Nano 06, no 04 (août 2011) : 325–32. http://dx.doi.org/10.1142/s1793292011002688.
Texte intégralMoon, Hyeon-Min, Jin-Sung Park, Il-Buem Lee, Young-Im Kang, Hae Jun Jung, Dongju An, Yumi Shin et al. « Cisplatin fastens chromatin irreversibly even at a high chloride concentration ». Nucleic Acids Research 49, no 21 (23 novembre 2021) : 12035–47. http://dx.doi.org/10.1093/nar/gkab922.
Texte intégralKarayay, Betül, Heidi Olze et Agnieszka J. Szczepek. « Degranulation of Murine Resident Cochlear Mast Cells : A Possible Factor Contributing to Cisplatin-Induced Ototoxicity and Neurotoxicity ». International Journal of Molecular Sciences 24, no 5 (27 février 2023) : 4620. http://dx.doi.org/10.3390/ijms24054620.
Texte intégralATAMAN, J. E., et A. A. A. OSINUBI. « EFFECTS OF ETHANOLIC LEAF EXTRACT OF NEWBOULDIA LAEVIS (P. BEAUV) ON CISPLATIN-INDUCED CHANGES ON TESTICULAR AND BLOOD PARAMETERS OF WISTAR RATS ». Nigerian Journal of Life Sciences (ISSN : 2276-7029) 4, no 1 (17 mars 2022) : 26–36. http://dx.doi.org/10.52417/njls.v4i1.152.
Texte intégralKumar, Gopal, Malvika H. Solanki, Xiangying Xue, Rachel Mintz, Swati Madankumar, Prodyot K. Chatterjee et Christine N. Metz. « Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity ». American Journal of Physiology-Renal Physiology 313, no 2 (1 août 2017) : F339—F350. http://dx.doi.org/10.1152/ajprenal.00688.2016.
Texte intégralAbedini Nazari, Najmeh, Behnam Omidi Sarajar, Seyedeh Zohreh Azarshin, Fatemeh Javani Jouni, Zahra Razzaghi et Jaber Zafari. « Overcoming Cisplatin’s Challenges : A Promising Future in Cancer Care ; A Comprehensive Review ». International Journal of Medical Toxicology and Forensic Medicine 13, no 04 (28 janvier 2024) : 43478. http://dx.doi.org/10.32598/ijmtfm.v13i4.43478.
Texte intégralSolanki, Malvika H., Prodyot K. Chatterjee, Madhu Gupta, Xiangying Xue, Andrei Plagov, Margot H. Metz, Rachel Mintz, Pravin C. Singhal et Christine N. Metz. « Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation ». American Journal of Physiology-Renal Physiology 307, no 4 (15 août 2014) : F369—F384. http://dx.doi.org/10.1152/ajprenal.00127.2014.
Texte intégralThèses sur le sujet "Cisplatin"
Amaral, Catia Lira do. « Efeito do resveratrol na nefrotoxicidade induzida pela cisplatina em ratos ». Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/60/60134/tde-22052007-090133/.
Texte intégralResveratrol (Res), a polyphenolic present in red wine, is known to possess potent antioxidant properties. The ability of resveratrol to protect against the nephrotoxicity of the antineoplastic agent cisplatin (cDDP) was evaluated in rats. The animals were treated with Res (25 mg/Kg body weight, ip., single dose) 30 minutes before administration of cDDP (5 mg/Kg body weight, ip., single dose) and then, sacrificed in 2 or 5 days followed by the treatment. After 5 days with resveratrol administration, the enhanced serum creatinine levels, urinary volume and urinary protein, which are indicative of renal injury, shown a significant reduction (p < 0.05). The cisplatintreated rats presented a tubular cell necrosis and increase immunostaining for ED1 and T-lymphocytes in the renal cortex and outer medulla. Those alterations were less intense in animals treated with resveratrol. After 2 days, administration of cisplatin to rats induced a higher malondialdehyde levels (MDA), and reduction in glutathione (GSH) concentrations in kidney tissue that were not prevented by resveratrol. In this study, the results indicate that resveratrol treatment attenuated the functional, histological and immunohistochemical renal alterations induced by cisplatin. The protect effect is relatated to the decrease of cells infiltrated at kidney tissue.
Santos, Graciela Cristina dos [UNESP]. « Avaliação do efeito protetor do urucum e da bixina sobre a genotoxicidade induzida pelo antitumoral cisplatina em células da linhagem PC12 ». Universidade Estadual Paulista (UNESP), 2008. http://hdl.handle.net/11449/100973.
Texte intégralUniversidade Estadual Paulista (UNESP)
A neuropatia induzida por drogas quimioterápicas é uma complicação no tratamento do câncer e outras doenças por ser freqüentemente dolorosa e requerer a interrupção da terapia. O antitumoral cisplatina é comumente usado contra muitas formas de câncer há aproximadamente 40 anos. Entretanto, sua aplicação é associada a muitos efeitos tóxicos, como neurotoxicidade, nefrotoxicidade, perda da audição e vômitos. Estes efeitos adversos têm levado ao desenvolvimento de agentes específicos para amenizar a toxicidade do fármaco. Alguns estudos sugerem que a administração de antioxidantes é capaz de reduzir os danos e proteger os tecidos. Dessa forma, os carotenóides são mais uma opção a ser avaliada, pois são considerados eficazes agentes antioxidantes. O urucum é uma fonte natural de corantes vermelhos e além da bixina (fração lipossolúvel do extrato), estão presentes nas suas sementes, outros carotenóides, como a norbixina, o bcaroteno, a criptoxantina, a luteína e a zeaxantina. Neste estudo, foi avaliada a genotoxicidade e a antigenotoxicidade do urucum e da bixina sobre a toxicidade induzida pelo antitumoral cisplatina em culturas de células PC12. A citotoxicidade foi determinada pelo método do MTT, a frequência de danos cromossômicos pelo Teste do Micronúcleo e a extensão de danos primários ao DNA pelo Ensaio do Cometa. O urucum e a bixina foram avaliados preliminarmente quanto a sua genotoxicidade. O urucum nas concentrações 0,2, 0,5 e 1,0 mg/mL e a bixina nas concentrações 0,05, 0,08 e 0,10 mg/mL não foram citotóxicos e nem genotóxicos às células PC12. Assim, essas concentrações foram utilizadas nos experimentos para verificar a proteção do urucum e da bixina contra os danos induzidos pela cisplatina. Embora o efeito protetor do urucum e da bixina não tenha sido evidente nos resultados obtidos pelo Ensaio do Cometa, eles se mostraram...
The neuropathy induced by chemotherapeutic drugs is a complication in the treatment of cancer and other diseases, because it is often painful and requires discontinuation of the therapy. Cisplatin has been commonly used against many forms of cancer for approximately 40 years. However, its application is associated with many toxic effects such as neurotoxicity, nephrotoxicity, hearing loss and vomiting. These adverse effects have led to the development of specific agents to lessen the toxicity of the drug. Some studies have suggested that the administration of antioxidants is able to reduce the damage and protect the tissues. Thus, the carotenoids are one more option to be evaluated, because they are considered to be effective antioxidants. Annatto is a natural source of red dyes and pigments and in addition to bixin (liposoluble fraction of the extract), other carotenoids are present in its seeds, such as norbixin, B-carotene, cryptoxanthin, lutein and zeaxanthin. In the present study, the genotoxicity and antigenotoxicity of annatto and bixin on the cisplatin induced-toxicity in PC12 cell cultures was assessed. Cytotoxicity was determined by the MTT assay, chromosomal damage by the Micronucleus test and the extent of primary damage to the DNA by the Comet assay. Annatto and bixin were first assessed with respect to their genotoxicity. Annatto concentrations of 0.2, 0.5 and 1.0 mg/ml and bixin concentrations of 0.05, 0.08 and 0.10 mg/ml were neither cytotoxic nor genotoxic to the PC12 cells. Thus, these concentrations were used in experiments to verify the protective effect of annatto and bixin against damage induced by cisplatin. Although the protective effect of annatto and bixin was not evident in the results obtained by the Comet assay, effective inhibition of the chromosomal damage (Micronucleus test) induced by cisplatin was shown. Annatto and bixin protected... (Complete abstract click electronic access below)
Santos, Graciela Cristina dos. « Avaliação do efeito protetor do urucum e da bixina sobre a genotoxicidade induzida pelo antitumoral cisplatina em células da linhagem PC12 / ». Araraquara : [s.n.], 2008. http://hdl.handle.net/11449/100973.
Texte intégralAbstract: The neuropathy induced by chemotherapeutic drugs is a complication in the treatment of cancer and other diseases, because it is often painful and requires discontinuation of the therapy. Cisplatin has been commonly used against many forms of cancer for approximately 40 years. However, its application is associated with many toxic effects such as neurotoxicity, nephrotoxicity, hearing loss and vomiting. These adverse effects have led to the development of specific agents to lessen the toxicity of the drug. Some studies have suggested that the administration of antioxidants is able to reduce the damage and protect the tissues. Thus, the carotenoids are one more option to be evaluated, because they are considered to be effective antioxidants. Annatto is a natural source of red dyes and pigments and in addition to bixin (liposoluble fraction of the extract), other carotenoids are present in its seeds, such as norbixin, B-carotene, cryptoxanthin, lutein and zeaxanthin. In the present study, the genotoxicity and antigenotoxicity of annatto and bixin on the cisplatin induced-toxicity in PC12 cell cultures was assessed. Cytotoxicity was determined by the MTT assay, chromosomal damage by the Micronucleus test and the extent of primary damage to the DNA by the Comet assay. Annatto and bixin were first assessed with respect to their genotoxicity. Annatto concentrations of 0.2, 0.5 and 1.0 mg/ml and bixin concentrations of 0.05, 0.08 and 0.10 mg/ml were neither cytotoxic nor genotoxic to the PC12 cells. Thus, these concentrations were used in experiments to verify the protective effect of annatto and bixin against damage induced by cisplatin. Although the protective effect of annatto and bixin was not evident in the results obtained by the Comet assay, effective inhibition of the chromosomal damage (Micronucleus test) induced by cisplatin was shown. Annatto and bixin protected... (Complete abstract click electronic access below)
Orientador: Maria de Lourdes Pires Bianchi
Coorientador: Antonio Cardozo dos Santos
Banca: Alessandro de Oliveira Rios
Banca: Daisy Maria Fávero Salvadori
Banca: João Bosco Faria
Banca: Cecilia Rodrigues Silva
Doutor
Kullmann, Maximilian [Verfasser]. « Identifying intracellular cisplatin interaction partners and assessing their contribution to cisplatin resistance / Maximilian Kullmann ». Bonn : Universitäts- und Landesbibliothek Bonn, 2016. http://d-nb.info/111988876X/34.
Texte intégralHadi, Sutopo. « The chemistry of cisplatin metabolites / ». [St. Lucia, Qld.], 2007. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe19800.pdf.
Texte intégralZhang, Jin-Gang. « Cisplatin nephrotoxicity : mechanisms and antidotes ». Thesis, University of Liverpool, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307635.
Texte intégralCastro, João Humberto Teotônio de [UNESP]. « Avaliação do espermograma de cães submetidos à administração de cisplatina ». Universidade Estadual Paulista (UNESP), 2007. http://hdl.handle.net/11449/89030.
Texte intégralCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
A correta orientação do Médico Veterinário, aos proprietários de cães, usados com finalidades reprodutivas, submetidas à quimioterapia com cisplatina, é importante na medida que este agente citostático age nas células em constante divisão, podendo ser citotóxicos para as células germinativas testiculares. O objetivo desse trabalho foi avaliar a qualidade espermática através do espermograma de cães que receberam cisplatina em diferentes momentos de análise espermática. A dose utilizada foi de 70 mg/mø, em intervalos de 21 dias, totalizando 4 infusões. Os cães foram divididos em dois grupos de 4 animais cada, sendo que um dos grupos recebeu a quimioterapia e o protocolo de diurese para proteção renal, já o grupo controle não recebeu a cisplatina, estando sujeito apenas aos fatores ambientais. Os resultados obtidos demonstraram que a cisplatina influenciou na qualidade espermática de cães, pois elevou as patologias maiores e totais acima do aceitável para cães aptos a reprodução. Portanto, infere-se que este citostático possa acarretar alterações morfofuncionais nos túbulos seminíferos e conduto epididimário.
The correct veterinary`s orientation for male dogs` owners used for reproduction goals, undergone cisplatin administration, is important because of this cistostatic act in cell with frequently proliferation, and could to cause germ cell injury. The objections of this experiment was to analysis the sperm quality through dogs` spermogram that received cisplatin`s infusions. The dose used was 70 mg/mø in 21 days periods, with 4 infusion in total. The dogs were divided in 2 groups with 4 animal each one. One of the groups received all the diuresys protocol (to protect the kidney) and the citostatic. And the other control group just didn`t receive the cisplatin infusion to know the real action of cisplatin effects without environmental stresses. The results show that cisplatin influence at the sperm quality in the dogs, because it elevated the major and total defects above that would be acceptable for competent dog to reproduct. It could deduct that cisplatin cause phisiologic alteration in the testis and epididymis.
Oliva, Carlos Alfredo Calpa [UNESP]. « Hemograma e teores séricos de Na, K, Mg, Ca e P de cães hígidos submetidos à administração de cisplatina ». Universidade Estadual Paulista (UNESP), 2007. http://hdl.handle.net/11449/89087.
Texte intégralA cisplatina é um fármaco antineoplásico utilizado como adjuvante no tratamento de diversas neoplasias. Neste estudo foram avaliados o hemograma e os teores de sódio, potássio, magnésio, cálcio e fósforo do soro sanguíneo de cães submetidos à terapia com cisplatina. Foram utilizados oito cães, machos, sem raça definida, com 10 a 15 kg de peso, clinicamente sadios. Os cães foram distribuídos em dois grupos, contendo 4 animais cada, sendo que os animais do grupo 1 receberam cisplatina e aqueles do grupo 2 não receberam cisplatina. Os cães do grupo 1 receberam quimioterapia e protocolo de diurese para proteção renal, já o grupo controle 2 não recebeu a cisplatina, estando sujeito apenas aos fatores ambientais. Os animais do grupo 1 foram submetidos a quatro sessões de quimioterapia com cisplatina na dose de 70mg/mø, administrada por via intravenosa, durante 20 minutos, no intervalo de 21 dias. Antes da administração da cisplatina, realizou-se fluidoterapia com solução fisiológica a 0,9% na dose de 25mL/kg/hora, por via intravenosa, durante duas horas, e depois por mais uma hora. Todos os animais receberam metoclopramida na dose de 2mg/kg, por via intravenosa, 15 minutos antes da administração da cisplatina e furosemida na dose de 2 mg/kg, por via intravenosa, 5 minutos após administração de metoclopramida. As amostras foram processadas e analisadas antes de cada sessão de quimioterapia. Os resultados mostraram que não houve diferença significativa entre os grupos para as contagens de hemácias, concentração de hemoglobina, hematócrito e contagem de leucócitos, mesmo assim as concentrações séricas de eletrólitos mantiveram-se dentro dos padrões da normalidade. Os resultados obtidos podem ser indicativos de que o protocolo empregado para o grupo 1 se mostrou efetivo para manter as características do hemograma e a concentração sérica dos eletrólitos.
The cisplatin is an antineoplasic drug used like adjunct treatment of various neoplasms. In this study, one evaluated the hemogram and sodium, potassium, magnesium, calcium and phosphorus levels in the dogs` blood under administration of cisplatin. One used 8 male dogs, with no definite race, weighing from 10 to 15 kilograms, and clinically healthy. The dogs were divided into two groups of 4 animals each, being group 1 treated with cisplatin and group 2 with no cisplatin. Group 1 received chemotherapy and the diurese protocol for kidney protection, group 2 did not receive cisplatin, being exposed only to the environmental factors. The animals from group 1 were submitted to four chemotherapy sessions with cisplatin 70mg/m2 administered intravenously for 20 minutes, in a 21 days interval before the cisplatin administration, one carried out a fluidotherapy with physiologic solution 0,9% on a dosage of 25mg/kg/hour intravenously during 2 hours, and posteriorly for one more hour. All the animals received methoclopramid intravenously on a dosage of 2mg/kg, 15 minutes before the cisplatin and furosemide administration on a 2mg/kg dosage, 5 minutes before the cisplatin infusion. The evaluation of the hemogram and the electrolytes levels above mentioned were done before each chemotherapy session. The results demonstrate that there were no significant differences among the groups for red blood cells counting, hemoglobin concentration, hematocrit and leucocytes counting, but still, the electrolytes seric concentration maintained itself in a normal standard. The results obtained may indicate that the protocol employed for group 1 showed efficiency to maintain the characteristics of the hemogram and the electrolytes seric concentration.
Li, Yan Julia. « Cisplatin-induced cytotoxicity in MDCK cells ». Thesis, University of Ottawa (Canada), 2002. http://hdl.handle.net/10393/6408.
Texte intégralBrock, Penelope. « Cisplatin toxicity in infants and children / ». Leuven : Leuven University Press, 1994. http://www.gbv.de/dms/bs/toc/190814756.pdf.
Texte intégralLivres sur le sujet "Cisplatin"
Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Syracuse, N.Y : Bristol-Myers Oncology Division, 1985.
Trouver le texte intégralChu, Wendy. Mechanism of cisplatin resistance inhuman malignant melanoma. Ottawa : National Library of Canada, 1998.
Trouver le texte intégralYoshihiro, Kikuchi, dir. Mechanism of cisplatin resistance and its circumvention. Commack, NY : Nova Science Publishers, 1998.
Trouver le texte intégralMerazga, Yamina. Aspects of the interaction between cisplatin and renal glutathione. Uxbridge : Brunel University, 1990.
Trouver le texte intégral1946-, Lippert Bernhard, dir. Cisplatin : Chemistry and biochemistry of a leading anticancer drug. Zürich : Verlag Helvetica Chimica Acta, 1999.
Trouver le texte intégralMorley, Christopher. Analogues of cisplatin from diamino carbohydrates and related compounds. Norwich : University of East Anglia, 1986.
Trouver le texte intégralEvans, Dyfed Llyr. The induction of apoptosis by the anticancer agent cisplatin. Manchester : Universityof Manchester, 1994.
Trouver le texte intégralLaurell, Göran. Ototoxicity of the anticancer drug cisplatin : Clinical and experimental aspects. Stockholm, Sweden : Distributed by Almqvist & Wiksell Periodical Co., 1991.
Trouver le texte intégralInstitut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab (nicht kleinzelliges Lungenkarzinom : Nutzenbewertung gemäß § 35a SGB V. Köln : Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2017.
Trouver le texte intégralBryant, Eric Edward. Systems Genetics of DNA Damage Tolerance – Cisplatin, RAD5 & CRISPR-mediated Nonsense. [New York, N.Y.?] : [publisher not identified], 2019.
Trouver le texte intégralChapitres de livres sur le sujet "Cisplatin"
Rosenberg, Barnett. « Platinum Complexes for the Treatment of Cancer : Why the Search Goes On ». Dans Cisplatin, 1–27. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch1.
Texte intégralAno, Susan O., Zsuzsanna Kuklenyik et Luigi G. Marzilli. « Structure and Dynamics of Pt Anticancer Drug Adducts from Nucleotides to Oligonucleotides as Revealed by NMR Methods ». Dans Cisplatin, 247–91. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch10.
Texte intégralChen, Yu, Zijian Guo et Peter J. Sadler. « 195Pt- and 15N-NMR Spectroscopic Studies of Cisplatin Reactions with Biomolecules ». Dans Cisplatin, 293–318. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch11.
Texte intégralBau, Robert, et Michal Sabat. « Structural Aspects of Pt-Purine Interactions : From Models to DNA ». Dans Cisplatin, 319–37. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch12.
Texte intégralReedijk, Jan, et Jan Maarten Teuben. « Platinum-Sulfur Interactions Involved in Antitumor Drugs, Rescue Agents, and Biomolecules ». Dans Cisplatin, 339–62. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch13.
Texte intégralAppleton, Trevor G. « Diammine- and Diamineplatinum Complexes with Non-Sulfur-Containing Amino Acids and Peptides ». Dans Cisplatin, 363–76. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch14.
Texte intégralLippert, Bernhard. « Platinum Blues : On the Way toward Unraveling a Mystery ». Dans Cisplatin, 377–403. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch15.
Texte intégralRandaccio, Lucio, et Ennio Zangrando. « Heteronuclear PtII Complexes with Pyrimidine Nucleobases ». Dans Cisplatin, 405–28. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch16.
Texte intégralNatile, Giovanni, Francesco P. Intini et Concetta Pacifico. « Diplatinum(III) Complexes : Chemical Species More Widely Spread Than Suspected ». Dans Cisplatin, 429–53. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch17.
Texte intégralMatsumoto, Kazuko. « Inorganic and Organometallic Chemistry of Cisplatin-Derived Diplatinum(III) Complexes ». Dans Cisplatin, 455–75. Zürich : Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch18.
Texte intégralActes de conférences sur le sujet "Cisplatin"
Absar, Saheem, Mujibur Khan, Kyle Edwards et David Calamas. « Electrospinning of Cisplatin-Loaded Cellulose Nanofibers for Cancer Drug Delivery ». Dans ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-37182.
Texte intégralCamargo, Luana Cristina, Joao Paulo Figueiro Longo, Karen Letycia Rodrigues de Paiva, Marina Mesquita Simões, Thais Bergmann et Victor Carlos Mello da Silva. « Immunotherapy vaccines for triple-negative breast cancer and its influence on the tumor microenvironment ». Dans Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1024.
Texte intégralLau, KingWun. « Brief summary of cisplatin nephrotoxicity ». Dans International Conference on Biological Engineering and Medical Science (ICBIOMed2022), sous la direction de Gary Royle et Steven M. Lipkin. SPIE, 2023. http://dx.doi.org/10.1117/12.2669859.
Texte intégralSoodvilai, Sirima, Sunhapas Soodvilai, Warayuth Sajomsang, Theerasak Rojanarata, Prasopchai Patrojanasophon et Praneet Opanasopit. « Chitosan Polymeric Micelles for Prevention of Cisplatin-Induced Nephrotoxicity and Anticancer Activity of Cisplatin ». Dans ICBET 2020 : 2020 10th International Conference on Biomedical Engineering and Technology. New York, NY, USA : ACM, 2020. http://dx.doi.org/10.1145/3397391.3397438.
Texte intégralLee, Chunman, Masao Sasai et Yoshiki Sawa. « Abstract 4452 : Controlled release complex of cisplatin for mesothelioma : gamma-PGA/Cisplatin complex formulation ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4452.
Texte intégralLiang, Xiaobing, Michael D. Mueller et Jing Jie Yu. « Abstract 2982 : Activation of checkpoint kinase Chk2 by cisplatin and its role in cisplatin resistance ». Dans Proceedings : AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010 ; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2982.
Texte intégralAbdullah, N., N. Al Balushi, S. Al-Bahlani, S. Dobretsov, I. Hassan, T. Sang, Y. Tamimi et I. Burney. « EP765 The effect of malformina1 on cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines ». Dans ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.816.
Texte intégralLarisch, C., T. Markowiak, S. Golovchenko, P. Bednarski, K. Müller, C. Großer, H.-S. Hofmann et M. Ried. « Dosis-abhängige Cisplatin-Konzentration und -Eindringtiefe in humanes Lungengewebe bei Inkubation in hyperthermer Cisplatin-Lösung ». Dans 32. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1771119.
Texte intégralGupta, Vikas, Ashok Kumar Chauhan, Paramjeet Kaur, Anil Khurana, Yashpal Verma et Nupur Bansal. « Comparative evaluation of concomitant chemoradiation with weekly cisplatin and gemcitabine versus weekly cisplatin in the management of locally advanced carcinoma of uterine cervix ». Dans 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685264.
Texte intégralRichards, Elizabeth J., William O. Cookson, Sanjay Popat et Miriam F. Moffatt. « Transcriptome Changes Accompanying Induced Cisplatin Resistance ». Dans American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4918.
Texte intégralRapports d'organisations sur le sujet "Cisplatin"
Turchi, John J. Proteomic Analysis of Cisplatin-Resistant Ovarian Cancer. Fort Belvoir, VA : Defense Technical Information Center, mars 2004. http://dx.doi.org/10.21236/ada425620.
Texte intégralTurchi, John. Proteomic Analysis of Cisplatin-Resistant Ovarian Concers. Fort Belvoir, VA : Defense Technical Information Center, mars 2006. http://dx.doi.org/10.21236/ada462560.
Texte intégralTurchi, John J. Proteomic Analysis of Cisplatin-Resistant Ovarian Concers. Fort Belvoir, VA : Defense Technical Information Center, mars 2005. http://dx.doi.org/10.21236/ada463194.
Texte intégralBalaji, Kethandapatti C. MT 2A Phosphorylation by PKC Mu/PKD Influences Chemosensitivity to Cisplatin in Prostate Cancer. Fort Belvoir, VA : Defense Technical Information Center, novembre 2008. http://dx.doi.org/10.21236/ada495664.
Texte intégralAllworth, Ann E. The Role of Terbium and Gadolinium in Reversal of Cisplatin Resistance in Cultured Human Breast Cancer Cells. Fort Belvoir, VA : Defense Technical Information Center, juin 2001. http://dx.doi.org/10.21236/ada414791.
Texte intégralMiao, Fang, Yaru Guo, Yan Yuan, Juzhou Chen et Yong Xin. Bevacizumab combined with pemetrexed plus carboplatin or cisplatin in the treatment of malignant pleural effusion of lung cancer : A meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, avril 2022. http://dx.doi.org/10.37766/inplasy2022.4.0096.
Texte intégralWang, Dandan, Shuaihang Hu, Kangdi Cao, Chenxi Qiao, Zhuo Wang et Wei Hou. Clinical efficacy and safety of Chinese herb injections combination with Docetaxel combined with cisplatin (DP) chemotherapy for advanced non-small cell lung cancer : A protocol for Bayesian network meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, septembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0081.
Texte intégralLi, Qian, Hua Xiao, Ren-long Liang, Qian-ru Yu, De-qing Tian, Li-na Zhao, Wen-wen Wang et Xiao-jia Yong. Efficacy and safety of Cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, juin 2020. http://dx.doi.org/10.37766/inplasy2020.6.0091.
Texte intégralHealth hazard evaluation report : HETA-2009-0121-3106, evaluation of exposures to healthcare personnel from cisplatin during a mock interperitoneal operation, University Medical Center, Las Vegas, Nevada. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, mars 2010. http://dx.doi.org/10.26616/nioshheta200901213106.
Texte intégral